GlassScriptPhysician profile
Irfan Munir
NPI 1073515086
$5,175.38
in general payments reported to CMS, 2019-2025
35 companies · $1,001 in 2025
The $1,001 reported for 2025 was more than what 78% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $832 · 2020: $417 · 2021: $615 · 2022: $578 · 2023: $724 · 2024: $1,008 · 2025: $1,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,587 · Education: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,586.80 |
| Education | $147.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $824.20 | 2019-2025 | Farxiga |
| Akebia Therapeutics INC | $578.37 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $466.09 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $369.16 | 2020-2025 | Jynarque |
| Vifor Pharma, INC. | $367.39 | 2019-2023 | Veltassa |
| Fresenius USA Marketing, INC. | $326.42 | 2019-2025 | Velphoro, Velphoro |
| Travere Therapeutics, INC. | $231.83 | 2023-2025 | |
| Opko Pharmaceuticals, LLC | $196.19 | 2019-2024 | Rayaldee |
| Amgen INC. | $168.09 | 2019-2025 | Krystexxa, Tavneos |
| Calliditas Therapeutics US INC. | $160.85 | 2023-2025 | Tarpeyo |
| Mallinckrodt Enterprises LLC | $156.26 | 2019 | |
| Novartis Pharmaceuticals Corporation | $139.72 | 2023-2025 | |
| Glaxosmithkline, LLC. | $132.41 | 2022-2024 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.52 | 2022-2025 | Jardiance |
| Bard Peripheral Vascular, INC. | $100.69 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $100.13 | 2021-2025 | Terlivaz |
| Horizon Therapeutics Plc | $95.19 | 2020-2022 | |
| Aurinia Pharma U.S., INC. | $95.11 | 2021-2023 | Lupkynis |
| Ardelyx, INC. | $84.07 | 2024-2025 | Ibsrela |
| Nxstage Medical, INC. | $71.54 | 2019 | |
| Novo Nordisk INC | $68.81 | 2025 | Ozempic |
| Baxter Healthcare | $54.53 | 2019 | |
| Cormedix INC. | $44.80 | 2024-2025 | Defencath, Defencath |
| Ultragenyx Pharmaceutical INC. | $26.55 | 2023 | |
| Kyowa Kirin, INC. | $25.25 | 2025 | |
| Scpharmaceuticals INC. | $24.31 | 2025 | |
| Alnylam Pharmaceuticals INC. | $23.52 | 2023 | Onpattro |
| Vertex Pharmaceuticals Incorporated | $22.25 | 2024 | |
| Xeris Pharmaceuticals, INC. | $20.02 | 2025 | Keveyis |
| Alexion Pharmaceuticals, INC. | $19.93 | 2023 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $16.43 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $15.91 | 2024 | |
| Cycle Pharmaceuticals INC | $14.97 | 2025 | Venxxiva |
| Shire North American Group INC | $11.45 | 2019 | |
| Daiichi Sankyo INC. | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irfan Munir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.